var data={"title":"Retinoblastoma: Clinical presentation, evaluation, and diagnosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Retinoblastoma: Clinical presentation, evaluation, and diagnosis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Paul L Kaufman, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Jonathan Kim, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Jesse L Berry, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Evelyn A Paysse, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Alberto S Pappo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Carrie Armsby, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 22, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Retinoblastoma is the most common primary intraocular malignancy of childhood and accounts for 10 to 15 percent of cancers that occur within the first year of life [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/1\" class=\"abstract_t\">1</a>]. Retinoblastoma typically presents as leukocoria (<a href=\"image.htm?imageKey=PEDS%2F56724\" class=\"graphic graphic_picture graphicRef56724 \">picture 1</a>) in a child under the age of two years. Untreated retinoblastoma is a deadly disease; however, with advances in treatment, survival in the contemporary era is &gt;95 percent. Prompt referral to an ocular oncologist and appropriate management by a multidisciplinary team are necessary to optimize visual outcome and survival.</p><p>The clinical presentation, evaluation, and diagnosis of retinoblastoma are reviewed here. The treatment and prognosis of retinoblastoma and the approach to children with leukocoria are discussed separately. (See <a href=\"topic.htm?path=retinoblastoma-treatment-and-outcome\" class=\"medical medical_review\">&quot;Retinoblastoma: Treatment and outcome&quot;</a> and <a href=\"topic.htm?path=approach-to-the-child-with-leukocoria\" class=\"medical medical_review\">&quot;Approach to the child with leukocoria&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3887962286\"><span class=\"h1\">TERMINOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Retinoblastoma occurs in heritable and nonheritable forms (<a href=\"image.htm?imageKey=ONC%2F73602\" class=\"graphic graphic_figure graphicRef73602 \">figure 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Heritable retinoblastoma</strong> &ndash; Heritable (also called hereditary, familial, or germline) retinoblastoma is associated with germline mutations (ie, mutations that occur in reproductive cells [sperm and eggs]) in the retinoblastoma (<a href=\"http://omim.org/entry/614041&amp;token=O25AxH2ZrpTPG8o+GEGTWOAxlaBzDNGkRHcLvzR6sVvwX6l30r9e40DCYKy02zwR&amp;TOPIC_ID=6275\" target=\"_blank\" class=\"external\">RB1</a>) gene. The term &quot;heritable retinoblastoma&quot; includes patients with bilateral disease, multifocal disease, those with a positive family history, and those with known germline mutations. Of note, approximately 15 percent of unilateral retinoblastoma cases are also due to germline mutations and are therefore heritable. In addition, most cases of heritable retinoblastoma result from de novo mutations and the family history is positive in only approximately 25 percent. Hence, a negative family history does not exclude heritable retinoblastoma. (See <a href=\"#H3\" class=\"local\">'Genetic predisposition'</a> below and <a href=\"#H9\" class=\"local\">'Family history'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Nonheritable retinoblastoma</strong> &ndash; Nonheritable (also called nonhereditary, nonfamilial, sporadic, or somatic) retinoblastoma results from somatic mutations (ie, mutations that occur in nonreproductive cells) in the <em>RB1</em> gene. Patients with nonheritable retinoblastoma have unilateral, unifocal disease and tend to be diagnosed at a later age compared with heritable cases. Though the term &quot;sporadic&quot; is commonly used to describe nonheritable retinoblastoma, this is somewhat of a misnomer, since many sporadic cases (ie, cases without a prior family history) are actually due to de novo germline mutations and therefore are heritable.</p><p/><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span></p><p class=\"headingAnchor\" id=\"H28685345\"><span class=\"h2\">Incidence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Retinoblastoma occurs in approximately 1 in 15,000 to 1 in 16,600 live births in the United States and Northern Europe [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/2-4\" class=\"abstract_t\">2-4</a>]. Retinoblastoma accounts for 13 percent of cancer in the first year of life [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/1\" class=\"abstract_t\">1</a>]. Between 2005 and 2009, the annual incidence of retinoblastoma in the United States among children &lt;15 years old was 4.1 per million [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/5\" class=\"abstract_t\">5</a>].</p><p>The median age at diagnosis is 18 to 20 months; an average of 12 months for children with bilateral disease and 24 months for children with unilateral disease [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/6,7\" class=\"abstract_t\">6,7</a>]. Approximately 95 percent of children with retinoblastoma present before the age of five years (<a href=\"image.htm?imageKey=PEDS%2F50453\" class=\"graphic graphic_figure graphicRef50453 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/2\" class=\"abstract_t\">2</a>]. Nonetheless, cases of newly diagnosed retinoblastoma have been reported in children as old as 18 years [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/8-11\" class=\"abstract_t\">8-11</a>] and, rarely, even in adults [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/12-14\" class=\"abstract_t\">12-14</a>]. The incidence is similar in boys and girls, and there is no racial predilection [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Genetic predisposition</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Retinoblastoma occurs in heritable and nonheritable forms (<a href=\"image.htm?imageKey=ONC%2F73602\" class=\"graphic graphic_figure graphicRef73602 \">figure 1</a>). Germline mutations in the retinoblastoma (<a href=\"http://omim.org/entry/614041&amp;token=O25AxH2ZrpTPG8o+GEGTWOAxlaBzDNGkRHcLvzR6sVvwX6l30r9e40DCYKy02zwR&amp;TOPIC_ID=6275\" target=\"_blank\" class=\"external\">RB1</a>) gene are present in approximately 40 percent of cases, predominantly in bilateral disease. Children with nonheritable retinoblastoma incur new somatic mutations in one retinal cell from which the tumor arises. Less than 10 percent of retinoblastoma patients have a positive family history for the disease, suggesting that the majority of cases arise from somatic mutations or de novo germline mutations [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/15\" class=\"abstract_t\">15</a>].</p><p>Bilateral retinoblastoma (which comprises approximately one-third of retinoblastoma cases) by definition results from germline mutations in the <em>RB1</em> gene [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/2,16\" class=\"abstract_t\">2,16</a>]. Bilateral tumors occur more commonly among younger children, consistent with the presence of a germline rather than somatic mutation (<a href=\"image.htm?imageKey=ONC%2F73602\" class=\"graphic graphic_figure graphicRef73602 \">figure 1</a>). However, there is a broad spectrum of age at presentation for both bilateral and unilateral disease and age should not preclude genetic evaluation of patients with unilateral disease (<a href=\"image.htm?imageKey=PEDS%2F50453\" class=\"graphic graphic_figure graphicRef50453 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/2,17,18\" class=\"abstract_t\">2,17,18</a>]. Germline mutations are seen in approximately 15 percent of patients with unilateral disease (which comprise approximately two-thirds of retinoblastoma cases) [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/18,19\" class=\"abstract_t\">18,19</a>]. Multifocal, unilateral disease suggests the presence of a germline mutation. (See <a href=\"#H13\" class=\"local\">'Genetic testing'</a> below.)</p><p>The genetic abnormality associated with heritable retinoblastoma also is associated with an increased risk of developing second malignancies, including osteogenic sarcoma, soft tissue sarcomas (particularly leiomyosarcoma) and malignant melanoma [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/20-25\" class=\"abstract_t\">20-25</a>]. (See <a href=\"topic.htm?path=pathogenetic-factors-in-soft-tissue-and-bone-sarcomas#H5\" class=\"medical medical_review\">&quot;Pathogenetic factors in soft tissue and bone sarcomas&quot;, section on 'Retinoblastoma'</a> and <a href=\"topic.htm?path=retinoblastoma-treatment-and-outcome#H1157807156\" class=\"medical medical_review\">&quot;Retinoblastoma: Treatment and outcome&quot;, section on 'Second malignancies'</a> and <a href=\"topic.htm?path=retinoblastoma-treatment-and-outcome#H2721783007\" class=\"medical medical_review\">&quot;Retinoblastoma: Treatment and outcome&quot;, section on 'Long-term follow-up'</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Retinoblastoma usually is caused by mutational inactivation of both alleles of the retinoblastoma (<a href=\"http://omim.org/entry/614041&amp;token=O25AxH2ZrpTPG8o+GEGTWOAxlaBzDNGkRHcLvzR6sVvwX6l30r9e40DCYKy02zwR&amp;TOPIC_ID=6275\" target=\"_blank\" class=\"external\">RB1</a>) gene [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/26\" class=\"abstract_t\">26</a>]. This gene maps to chromosome 13q14 and encodes a nuclear protein (Rb) that acts as a tumor suppressor [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/15,27-29\" class=\"abstract_t\">15,27-29</a>]. The Rb protein restricts the cell's ability to progress from the G1 phase to the S phase of the cell cycle [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/30\" class=\"abstract_t\">30</a>]. When active, Rb binds to E2F, a transcription factor. Loss of active, functional Rb causes cell cycle dysregulation. A &quot;two-hit&quot; model has been proposed to explain the different clinical features of heritable and nonheritable cases of retinoblastoma (<a href=\"image.htm?imageKey=ONC%2F73602\" class=\"graphic graphic_figure graphicRef73602 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/31-34\" class=\"abstract_t\">31-34</a>]. The cell of origin in retinoblastoma has been debated, but cone precursor cells appear to play a pivotal role in retinoblastoma tumorigenesis [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/35\" class=\"abstract_t\">35</a>].</p><p>In the heritable form, a germline mutation at the <em>RB1</em> locus (most common) or deletion of chromosome 13q (containing the <em>RB1</em> gene locus) is present in all cells of the body, and a second &quot;hit,&quot; occurring later in development, affects the remaining <em>RB1</em> allele within retinal cells [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/36-38\" class=\"abstract_t\">36-38</a>]. Patients with heritable retinoblastoma are at risk of multifocal and bilateral tumors. The second &quot;hit&quot; may be a second mutation in the <em>RB1</em> gene or silencing through epigenetic changes [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/39,40\" class=\"abstract_t\">39,40</a>]. Heritable retinoblastoma demonstrates incomplete penetrance, with approximately 90 percent of genotypic carriers expressing the malignancy. Certain families with heritable retinoblastoma have been identified with much lower penetrance, possibly related to genetic modifiers or only partial inactivation of the <em>RB1</em> gene (eg, inactivation of <em>SYK</em>, a proto-oncogene necessary for the growth of retinoblastoma cells) [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/39-42\" class=\"abstract_t\">39-42</a>]. Mosaicism for an <em>RB1</em> mutation may also result in disease [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/43\" class=\"abstract_t\">43</a>]. (See <a href=\"topic.htm?path=microdeletion-syndromes-chromosomes-12-to-22#H19035904\" class=\"medical medical_review\">&quot;Microdeletion syndromes (chromosomes 12 to 22)&quot;, section on '13q14 deletion syndrome (Retinoblastoma syndrome)'</a>.)</p><p>In most cases of nonheritable retinoblastoma, both allelic mutations arise spontaneously in a single somatic cell of the retina, resulting in the usual clinical scenario of a unifocal, unilateral tumor (<a href=\"image.htm?imageKey=ONC%2F73602\" class=\"graphic graphic_figure graphicRef73602 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/33,44\" class=\"abstract_t\">33,44</a>]. However, in a review of 1068 cases of unilateral nonheritable retinoblastoma, no <em>RB1</em> mutations were reported in 2.7 percent [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/45\" class=\"abstract_t\">45</a>]. Approximately one-half of the tumors in which no mutation was detected were associated with a high level of <em>MYCN</em> amplification. Normally, <em>MYCN</em> promotes cell cycle progression; when amplified, <em>MYCN</em> promotes unregulated cell proliferation. These tumors also showed a distinct histology (undifferentiated cells with large, prominent, multiple nucleoli; necrosis; apoptosis; little calcification), and early age of diagnosis (median age 4.5 months versus 24 months in children with <em>RB1</em> mutations). These observations suggest that <em>MYCN</em> amplification may initiate retinoblastoma in a small subset of patients without <em>RB1</em> mutations. Chromothripsis (a global event causing multiple simultaneous chromosome rearrangements at once) at the <em>RB1</em> locus also may initiate retinoblastoma in a small subset of patients [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/46\" class=\"abstract_t\">46</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">NATURAL HISTORY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Untreated, retinoblastoma is a deadly disease. The tumors grow to fill the eye and destroy the globe [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/31\" class=\"abstract_t\">31</a>]. Metastatic spread is typically diagnosed within the first 12 months of clinical presentation of retinoblastoma. In the United States, with treatment, the survival rate for retinoblastoma is &gt;95 percent [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/47\" class=\"abstract_t\">47</a>]. However, the prognosis for eye salvage is far lower and depends on the stage of disease at diagnosis. Spontaneous regression may occur in a small number of cases but is a rare occurrence [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/48-50\" class=\"abstract_t\">48-50</a>]. A small tumor with surrounding chorioretinal atrophy, called a retinoma or retinocytoma, can be a very rare benign manifestation of <em>RB1</em> mutation [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/51\" class=\"abstract_t\">51</a>].</p><p>The most common routes of metastatic spread are direct infiltration via the optic nerve to the central nervous system (CNS), or spread via the choroid into the sclera and into the orbit [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/52\" class=\"abstract_t\">52</a>]. Additional routes of spread include dispersion of the tumor cells through the subarachnoid space to the contralateral optic nerve or through the cerebrospinal fluid to the CNS; hematogenous dissemination to the lung, bone, liver, or brain; and lymphatic dissemination if the tumor spreads anteriorly into the conjunctivae, eyelids, or extraocular tissue. While cure rates for orbital recurrences remain high, the mortality rate for extra-orbital metastatic disease is greater than 50 percent [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/53,54\" class=\"abstract_t\">53,54</a>]. Even with modern treatment strategies, survival rates for CNS disease from metastatic retinoblastoma remain dismal (&lt;10 percent).</p><p>The most common cause of death for patients with heritable retinoblastoma is a secondary malignancy and not the initial primary retinoblastoma [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/55\" class=\"abstract_t\">55</a>]. (See <a href=\"topic.htm?path=retinoblastoma-treatment-and-outcome#H1157807156\" class=\"medical medical_review\">&quot;Retinoblastoma: Treatment and outcome&quot;, section on 'Second malignancies'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">CLINICAL PRESENTATION</span></p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Retinoblastoma typically presents as leukocoria (<a href=\"image.htm?imageKey=PEDS%2F56724\" class=\"graphic graphic_picture graphicRef56724 \">picture 1</a>) in a child under the age of two years. Other common presenting symptoms include strabismus (<a href=\"image.htm?imageKey=PEDS%2F74034\" class=\"graphic graphic_picture graphicRef74034 \">picture 2</a>), nystagmus, and a red inflamed eye [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/6,56\" class=\"abstract_t\">6,56</a>]. In one retrospective review of 1654 patients with retinoblastoma, the most common presenting signs were leukocoria (54 percent) and strabismus (19 percent); the mean age at diagnosis was 20 months [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/6\" class=\"abstract_t\">6</a>].</p><p>Because leukocoria is the most common finding of retinoblastoma, and also indicative of other diseases that may threaten vision, urgent referral to an ophthalmologist is warranted if leukocoria is seen. A child with strabismus should also be referred. (See <a href=\"topic.htm?path=evaluation-and-management-of-strabismus-in-children#H7\" class=\"medical medical_review\">&quot;Evaluation and management of strabismus in children&quot;, section on 'Strabismus'</a> and <a href=\"topic.htm?path=approach-to-the-child-with-leukocoria#H16\" class=\"medical medical_review\">&quot;Approach to the child with leukocoria&quot;, section on 'Referral'</a>.)</p><p>Less common presentations for retinoblastoma include decreased vision (4 percent), ocular inflammation (5 percent), and a known family history of the disease (5 percent) [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/6\" class=\"abstract_t\">6</a>]. Rare presentations include iris heterochromia, caused in some cases by neovascularization of the iris, called rubeosis iridis; vitreous hemorrhage (causing a dark rather than white light reflex) [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/57\" class=\"abstract_t\">57</a>]; hyphema in the absence of trauma; glaucoma; anisocoria; orbital cellulitis from tumor necrosis with proptosis; eye pain; and fever [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/6,31,58-61\" class=\"abstract_t\">6,31,58-61</a>]. In the United States, more than one-half of new patients present with advanced intraocular disease. Extraocular disease is more common at presentation in resource-limited countries [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/62\" class=\"abstract_t\">62</a>].</p><p>Signs and symptoms in children with metastatic disease may include anorexia or weight loss, vomiting, headache, neurologic impairment, orbital mass, or soft tissue mass [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/63\" class=\"abstract_t\">63</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Morphologic features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, the classic presentation of early retinoblastoma is a solitary or multifocal, well-circumscribed, translucent intraretinal mass. As the disease advances, the tumor becomes more pink in color, with dilated feeding blood vessels, and may exhibit one of three main growth patterns:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Exophytic</strong> &ndash; The vertical growth of the tumor is beneath the retina, toward and into the subretinal space, often leading to exudative retinal detachment. Tumor cells may break free and lead to subretinal seeds.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Endophytic</strong> &ndash; The vertical growth of the tumor is toward and into the vitreous cavity. The tumor is friable, and often, the vitreous is seeded with tumor cells. Tumor cells can enter the anterior chamber and layer behind the cornea, causing a pseudo-hypopyon. Spontaneous necrosis of the tumor can lead to a severe intraocular inflammatory response, presenting as pseudo-endophthalmitis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Diffuse infiltrating retinoblastoma</strong> &ndash; The tumor remains relatively flat (very little vertical growth) and grows intraretinally, mimicking retinitis. The ischemia that can occur leads to iris neovascularization (and iris heterochromia) in 50 percent of cases [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/64\" class=\"abstract_t\">64</a>]. Diffuse infiltrating retinoblastoma is the least common growth pattern (occurring in approximately 2 percent of cases), and tends to present unilaterally in older children.</p><p/><p>The growth pattern of retinoblastoma can vary as the tumor enlarges. An exophytic tumor can erode through the overlying retina and into the vitreous cavity, giving the clinical appearance of a combined exophytic-endophytic lesion (<a href=\"image.htm?imageKey=PEDS%2F55803\" class=\"graphic graphic_picture graphicRef55803 \">picture 3</a>). The pattern of tumor growth does not appear to be associated with clinical outcome [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/65\" class=\"abstract_t\">65</a>].</p><p>Classic pathological features of retinoblastoma include a small round blue cell tumor with Flexner-Wintersteiner rosette formation with clear central lumen (<a href=\"image.htm?imageKey=PEDS%2F99046\" class=\"graphic graphic_picture graphicRef99046 \">picture 4</a>), Homer-Wright rosettes, and fleurettes.</p><p class=\"headingAnchor\" id=\"H2732413387\"><span class=\"h2\">Trilateral retinoblastoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Trilateral retinoblastoma consists of unilateral or bilateral retinoblastoma associated with an intracranial tumor that is histologically similar [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/66\" class=\"abstract_t\">66</a>]. Approximately three-fourths of cases of trilateral retinoblastoma arise in the pineal gland (<a href=\"image.htm?imageKey=PEDS%2F98797\" class=\"graphic graphic_diagnosticimage graphicRef98797 \">image 1</a>), but tumors may also occur in the suprasellar or parasellar regions.</p><p>Intracranial tumors occur in approximately 5 percent of patients with bilateral or heritable retinoblastoma [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/66-69\" class=\"abstract_t\">66-69</a>]. In contrast, intracranial tumors are rare in cases of nonheritable unilateral retinoblastoma, occurring in &lt;0.5 percent of cases.</p><p>In &gt;50 percent of cases, the intracranial tumor is detected at the time of retinoblastoma diagnosis; the remaining tumors occur subsequent to initial diagnosis, typically before the age of five years. In one study, the mean age at diagnosis was 31 months, and the average interval between diagnosis of retinoblastoma and the intracranial tumor was 21 months [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/67\" class=\"abstract_t\">67</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Family history</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As previously discussed, patients with a positive family history of retinoblastoma are presumed to have heritable retinoblastoma due to an <a href=\"http://omim.org/entry/614041&amp;token=O25AxH2ZrpTPG8o+GEGTWOAxlaBzDNGkRHcLvzR6sVvwX6l30r9e40DCYKy02zwR&amp;TOPIC_ID=6275\" target=\"_blank\" class=\"external\">RB1</a> germline mutation and have a 50 percent risk of passing the mutation on to their offspring. Patients with an <em>RB1</em> germline mutation have a 90 percent chance of the mutation manifesting with retinoblastoma. Genetic testing is suggested in all children with retinoblastoma, as it can help assess the risk of retinoblastoma in other family members. (See <a href=\"#H13\" class=\"local\">'Genetic testing'</a> below.)</p><p>It is important to review the family history in children with retinoblastoma; however, the family history alone is insufficient to assess whether a child with retinoblastoma has the heritable or nonheritable form. The family history is negative in approximately 90 percent of children with retinoblastoma for the following reasons:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Only approximately 40 percent of cases are due to germline <em>RB1</em> mutations (ie, heritable form); whereas 60 percent of cases arise from somatic mutations and are not heritable. (See <a href=\"#H3\" class=\"local\">'Genetic predisposition'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Many cases of heritable retinoblastoma arise from de novo germline <em>RB1</em> mutations and, therefore, previously affected family members may be lacking. The offspring and siblings of these patients are at risk of developing retinoblastoma and should undergo genetic testing <span class=\"nowrap\">and/or</span> surveillance. (See <a href=\"#H2690789901\" class=\"local\">'Screening children at risk'</a> below and <a href=\"#H13\" class=\"local\">'Genetic testing'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One parent may be a silent carrier or may have somatic mosaicism for the <em>RB1</em> mutation [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/43\" class=\"abstract_t\">43</a>].</p><p/><p class=\"headingAnchor\" id=\"H2690789901\"><span class=\"h1\">SCREENING CHILDREN AT RISK</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infants and children who are at increased risk of retinoblastoma on the basis of a positive family history should undergo routine screening to facilitate early detection and treatment of disease. At-risk infants should initially be evaluated by an ophthalmologist with experience in retinoblastoma within the first 8 weeks of life. Screening examinations are then conducted as follows [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/31,70-72\" class=\"abstract_t\">31,70-72</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>During the first three years of life: Screening examinations are initially performed every one to two months and then spaced to every three months if there are no concerning findings.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Age three to seven years: Screening examinations are performed every four to six months.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If genetic testing reveals that the child does <strong>not</strong> have a germline <em>RB1</em> mutation, screening can be discontinued.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If genetic testing reveals that the child <strong>does</strong> carry an <em>RB1</em> mutation, she or he should undergo frequent screening throughout early childhood (as above) and then continue to have regular examinations every one to two years after age seven years.</p><p/><p>The interval of screening depends in part on the expected risk for retinoblastoma based on family history, which can be refined by genetic testing (see <a href=\"#H13\" class=\"local\">'Genetic testing'</a> below). The schedule described above is appropriate for patients at intermediate to high risk (eg, if the affected family member is a first-degree relative with bilateral retinoblastoma). It is reasonable to perform screening evaluations less frequently in children deemed to be at lower risk based on family history (eg, if the affected family member is a second-degree relative with unilateral retinoblastoma) [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/72\" class=\"abstract_t\">72</a>]. (See <a href=\"#H3\" class=\"local\">'Genetic predisposition'</a> above and <a href=\"#H9\" class=\"local\">'Family history'</a> above.)</p><p>Retinoblastoma surveillance examinations are usually performed with the patient under general anesthesia to permit complete detailed examination of the ocular fundus until age three to four years and then in the office thereafter at the discretion of the ophthalmologist. </p><p>The risk of anesthesia is balanced by the benefit of improved ocular survival. In one retrospective review of 1654 patients with retinoblastoma, those who had a positive family history and underwent surveillance for retinoblastoma from birth were diagnosed at a younger age and earlier stage of disease than those who had a positive family history and did not undergo prospective surveillance [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/6\" class=\"abstract_t\">6</a>]. In addition, prospectively screened patients had better ocular survival (71 versus 15 percent for unilateral tumors and 67 versus 43 percent for bilateral tumors).</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The evaluation in children with suspected retinoblastoma should be carried out in consultation with an ocular oncologist.</p><p class=\"headingAnchor\" id=\"H1910567001\"><span class=\"h2\">Disease extent</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In all patients, the evaluation includes the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete physical examination</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ophthalmologic examination under anesthesia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ocular ultrasonography</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Magnetic resonance imaging (MRI) of the brain and orbits</p><p/><p>Ophthalmoscopic examination under anesthesia permits complete visualization of the retina and identification of multifocal tumors <span class=\"nowrap\">and/or</span> subretinal or vitreous seeding. The characteristic finding is a chalky, off-white retinal mass with a soft, friable consistency [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/31,61\" class=\"abstract_t\">31,61</a>]. Intrinsic tumor calcification, tumor microvasculature, and seeding may also be seen. (See <a href=\"#H8\" class=\"local\">'Morphologic features'</a> above.)</p><p>Retinoblastoma is suggested on imaging studies if calcium is present within the mass (<a href=\"image.htm?imageKey=PEDS%2F98799%7EPEDS%2F72561\" class=\"graphic graphic_diagnosticimage graphicRef98799 graphicRef72561 \">image 2A-B</a>) and the globe is of normal size [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/7,73-75\" class=\"abstract_t\">7,73-75</a>]. MRI will not demonstrate calcifications; however, it is an important component of the evaluation in that it assesses tumor size, potential optic nerve involvement, and the presence of an associated intracranial tumor (ie, trilateral retinoblastoma). (See <a href=\"#H2732413387\" class=\"local\">'Trilateral retinoblastoma'</a> above.). </p><p>Retinoblastoma is characteristically bright on T1 and dark compared with the vitreous on T2 weighted MRI scans (<a href=\"image.htm?imageKey=PEDS%2F107994\" class=\"graphic graphic_diagnosticimage graphicRef107994 \">image 3</a>) [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/76\" class=\"abstract_t\">76</a>]. Computed tomography (CT) is generally avoided in patients with suspected retinoblastoma because of the risk of radiation-induced second cancers in patients with heritable disease; however, CT may occasionally be used for diagnostically challenging cases [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/77-80\" class=\"abstract_t\">77-80</a>]. (See <a href=\"topic.htm?path=retinoblastoma-treatment-and-outcome#H1157807156\" class=\"medical medical_review\">&quot;Retinoblastoma: Treatment and outcome&quot;, section on 'Second malignancies'</a>.)</p><p class=\"headingAnchor\" id=\"H2022885934\"><span class=\"h2\">Metastatic evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Metastatic disease is rarely present at the time of diagnosis, and formal staging studies (ie, bone marrow examination, lumbar puncture, <span class=\"nowrap\">and/or</span> radionuclide bone scan) are not routinely performed due to their low yield [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/81,82\" class=\"abstract_t\">81,82</a>].</p><p>If there is clear evidence of tumor outside the eye (ie, optic nerve invasion, or choroidal involvement that is extensive) a full metastatic evaluation may be pursued, including [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/83,84\" class=\"abstract_t\">83,84</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bone marrow aspiration and biopsy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lumbar puncture</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Radionuclide bone scan</p><p/><p>Metastatic evaluation may also be warranted in group E retinoblastoma (<a href=\"image.htm?imageKey=PEDS%2F78948\" class=\"graphic graphic_table graphicRef78948 \">table 1</a>), in which choroidal and optic nerve invasion are more common [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/85\" class=\"abstract_t\">85</a>]. Other risk factors for choroidal and optic nerve involvement include exophytic growth pattern, elevated intraocular pressure, tumor thickness &ge;15 mm, and iris neovascularization; however, the presence of these factors alone generally does not warrant performing a metastatic evaluation [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/86,87\" class=\"abstract_t\">86,87</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Genetic testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Molecular genetic testing is suggested for all affected patients (<a href=\"image.htm?imageKey=PEDS%2F88522\" class=\"graphic graphic_table graphicRef88522 \">table 2</a>). In heritable forms of retinoblastoma, molecular testing of peripheral white blood cells can identify the germline mutation in 90 to 95 percent of cases [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/71\" class=\"abstract_t\">71</a>]. Patients in whom germline mutations are identified should be referred to a clinical geneticist for testing of parents and siblings based upon the genetic mutation identified in the patient [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/72,88\" class=\"abstract_t\">72,88</a>].</p><p>Genetic testing and counseling are important aspects in the management of patients with retinoblastoma in order to estimate the risk of disease in family members and future offspring [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/89\" class=\"abstract_t\">89</a>]. It also can help parents understand the genetic consequences of each form of retinoblastoma, particularly as it relates to secondary cancers in children with heritable retinoblastoma. In addition, genetic testing can prevent unnecessary clinical screening of the patient's siblings [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/90\" class=\"abstract_t\">90</a>]. (See <a href=\"#H2690789901\" class=\"local\">'Screening children at risk'</a> above.)</p><p>In cases of unilateral disease, molecular testing should be performed initially on tumor cells (if available from enucleation) to identify the specific <a href=\"http://omim.org/entry/614041&amp;token=O25AxH2ZrpTPG8o+GEGTWOAxlaBzDNGkRHcLvzR6sVvwX6l30r9e40DCYKy02zwR&amp;TOPIC_ID=6275\" target=\"_blank\" class=\"external\">RB1</a> mutation. Identification of the mutation in the tumor increases the sensitivity of testing the peripheral blood in unilateral patients to determine if the disease is heritable or nonheritable. If tumor DNA is not available, routine genetic testing of the peripheral blood should be done.</p><p>The siblings and offspring of patients in whom germline mutations are identified should undergo genetic testing <span class=\"nowrap\">and/or</span> surveillance for tumor as described above. (See <a href=\"#H2690789901\" class=\"local\">'Screening children at risk'</a> above.)</p><p>If molecular genetic testing is not available or is uninformative, the family history and tumor presentation (eg, unilateral versus bilateral; unifocal versus multifocal) can be used to estimate the risk of retinoblastoma in family members, which ranges from &lt;1 to 45 percent (<a href=\"image.htm?imageKey=PEDS%2F68322\" class=\"graphic graphic_figure graphicRef68322 \">figure 3</a>).</p><p class=\"headingAnchor\" id=\"H2153944203\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of retinoblastoma can usually be made based on the dilated indirect ophthalmoscopic examination and imaging studies as described above. The characteristic finding is a chalky, off-white retinal mass with a soft, friable consistency. Pathology is not necessary to confirm the diagnosis. Biopsy is contraindicated because of the risk of tumor seeding. (See <a href=\"#H1910567001\" class=\"local\">'Disease extent'</a> above and <a href=\"#H8\" class=\"local\">'Morphologic features'</a> above.).</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">CLASSIFICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Retinoblastoma is classified according to the extent of disease and the likelihood of globe salvage. The International Classification for Intraocular Retinoblastoma is the classification system used by the Children's Oncology Group (COG) in multicenter treatment protocols (<a href=\"image.htm?imageKey=PEDS%2F78948\" class=\"graphic graphic_table graphicRef78948 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/91\" class=\"abstract_t\">91</a>]. Other classification systems include the Philadelphia and St. Jude classifications [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/92,93\" class=\"abstract_t\">92,93</a>]. The Reese-Ellsworth and Essen classifications were used previously; however, these systems are outdated and have limited clinical use in contemporary practice.</p><p class=\"headingAnchor\" id=\"H4020183147\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of retinoblastoma primarily includes other conditions that produce leukocoria. The approach to children with leukocoria is reviewed in greater detail separately. (See <a href=\"topic.htm?path=approach-to-the-child-with-leukocoria#H2\" class=\"medical medical_review\">&quot;Approach to the child with leukocoria&quot;, section on 'Causes of leukocoria'</a>.)</p><p>In a retrospective series of 2775 patients referred for management of retinoblastoma over a 40-year period, 22 percent were diagnosed with other conditions [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/94\" class=\"abstract_t\">94</a>]. The most common conditions varied depending on the age of the child [<a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/94,95\" class=\"abstract_t\">94,95</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&lt;1 year:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Persistent fetal vasculature (PFV) &ndash; 49 percent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Coats disease &ndash; 20 percent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Vitreous hemorrhage &ndash; 7 percent</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>1 to 2 years:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Coats disease &ndash; 58 percent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>PFV &ndash; 11 percent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Vitreous hemorrhage &ndash; 5 percent</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>2 to 5 years:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Coats disease &ndash; 61 percent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Toxocariasis &ndash; 8 percent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>PFV &ndash; 7 percent</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&gt;5 years:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Coats disease &ndash; 57 percent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Toxocariasis &ndash; 8 percent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Familial exudative vitreoretinopathy &ndash; 6 percent</p><p/><p>Clinical features (eg, age, family history, retinal mass, retinal calcification) help to distinguish these conditions from retinoblastoma. However, consultation with an ocular oncologist specializing in retinoblastoma is suggested to establish the diagnosis before formulating a treatment plan.</p><p class=\"headingAnchor\" id=\"H31\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Retinoblastoma is the most common primary intraocular malignancy of childhood and accounts for 10 to 15 percent of cancers within the first year of life. The majority of cases are diagnosed in children younger than two years of age. Approximately one-third of cases are bilateral. Children who have a family history of retinoblastoma or a personal or family history of 13q deletion have an increased risk of developing retinoblastoma. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Retinoblastoma occurs in heritable (approximately 40 percent of cases) and nonheritable (approximately 60 percent of cases) forms (<a href=\"image.htm?imageKey=ONC%2F73602\" class=\"graphic graphic_figure graphicRef73602 \">figure 1</a>). Heritable retinoblastoma is associated with germline mutations in the retinoblastoma (<a href=\"http://omim.org/entry/614041&amp;token=O25AxH2ZrpTPG8o+GEGTWOAxlaBzDNGkRHcLvzR6sVvwX6l30r9e40DCYKy02zwR&amp;TOPIC_ID=6275\" target=\"_blank\" class=\"external\">RB1</a>) gene. The nonheritable form results from somatic <em>RB1</em> mutations in the tumor only. Heritable retinoblastoma tends to present at an early age; most cases are bilateral <span class=\"nowrap\">and/or</span> multifocal, and approximately one-quarter have a positive family history. In contrast, children presenting with nonheritable retinoblastoma typically have unilateral and unifocal disease, have a negative family history, and usually present at a later age. (See <a href=\"#H3887962286\" class=\"local\">'Terminology'</a> above and <a href=\"#H3\" class=\"local\">'Genetic predisposition'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If untreated, retinoblastoma grows to fill the eye and destroys the internal architecture of the globe. Metastatic spread can begin within months, and death usually occurs within a year following metastasis. Spontaneous regression may occur in a small number of cases but is a rare occurrence. (See <a href=\"#H5\" class=\"local\">'Natural history'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Retinoblastoma typically presents as leukocoria (<a href=\"image.htm?imageKey=PEDS%2F56724\" class=\"graphic graphic_picture graphicRef56724 \">picture 1</a>) in a child under the age of two years. Other common presenting symptoms include strabismus (<a href=\"image.htm?imageKey=PEDS%2F74034\" class=\"graphic graphic_picture graphicRef74034 \">picture 2</a>), nystagmus, and red eye. (See <a href=\"#H6\" class=\"local\">'Clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Children with a family history of retinoblastoma should undergo clinical screening <span class=\"nowrap\">and/or</span> genetic testing for retinoblastoma. (See <a href=\"#H2690789901\" class=\"local\">'Screening children at risk'</a> above and <a href=\"#H13\" class=\"local\">'Genetic testing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The evaluation in children with suspected retinoblastoma is carried out in consultation with an ocular oncologist and includes (see <a href=\"#H12\" class=\"local\">'Evaluation'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Complete physical examination</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Ophthalmologic examination under anesthesia</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Ocular ultrasonography</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Magnetic resonance imaging of the brain and orbits</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Metastatic disease is rarely present at the time of diagnosis, and formal staging studies are not routinely performed. However, if there is clear evidence of tumor outside the eye, a full metastatic evaluation should be pursued, including (see <a href=\"#H2022885934\" class=\"local\">'Metastatic evaluation'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Bone marrow aspiration and biopsy</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Lumbar puncture</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Radionuclide bone scan</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Molecular genetic testing is suggested for all affected patients (<a href=\"image.htm?imageKey=PEDS%2F88522\" class=\"graphic graphic_table graphicRef88522 \">table 2</a>). Patients in whom germline mutations are identified should be referred to a clinical geneticist for testing of parents and siblings based upon the genetic mutation identified in the patient. (See <a href=\"#H13\" class=\"local\">'Genetic testing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of retinoblastoma can usually be made based on the dilated indirect ophthalmoscopic examination and imaging studies. The characteristic finding is a chalky, off-white retinal mass with a soft, friable consistency. Pathology is not necessary to confirm the diagnosis and biopsy is contraindicated because of the risk of tumor seeding. (See <a href=\"#H2153944203\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Retinoblastoma is classified according to the extent of disease and the likelihood of globe salvage (<a href=\"image.htm?imageKey=PEDS%2F78948\" class=\"graphic graphic_table graphicRef78948 \">table 1</a>). (See <a href=\"#H14\" class=\"local\">'Classification'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis of retinoblastoma primarily includes other conditions that produce leukocoria (eg, persistent fetal vasculature, Coats disease, and ocular toxocariasis). (See <a href=\"#H4020183147\" class=\"local\">'Differential diagnosis'</a> above and <a href=\"topic.htm?path=approach-to-the-child-with-leukocoria#H2\" class=\"medical medical_review\">&quot;Approach to the child with leukocoria&quot;, section on 'Causes of leukocoria'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1150401417\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Ronald Teed, MD, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2012 (Accessed on March 30, 2016).</li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/2\" class=\"nounderline abstract_t\">Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 2009; 93:21.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/3\" class=\"nounderline abstract_t\">Seregard S, Lundell G, Svedberg H, Kivel&auml; T. Incidence of retinoblastoma from 1958 to 1998 in Northern Europe: advantages of birth cohort analysis. Ophthalmology 2004; 111:1228.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/4\" class=\"nounderline abstract_t\">Gregersen PA, Urbak SF, Funding M, et al. Danish retinoblastoma patients 1943-2013 - genetic testing and clinical implications. Acta Oncol 2016; 55:412.</a></li><li class=\"breakAll\">Age-adjusted and age-specific SEER cancer incidence rates, 2005-200. http://seer.cancer.gov/csr/1975_2009_pops09/results_merged/sect_29_childhood_cancer_iccc.pdf (Accessed on February 25, 2013).</li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/6\" class=\"nounderline abstract_t\">Abramson DH, Beaverson K, Sangani P, et al. Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival. Pediatrics 2003; 112:1248.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/7\" class=\"nounderline abstract_t\">Abramson DH, Frank CM, Susman M, et al. Presenting signs of retinoblastoma. J Pediatr 1998; 132:505.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/8\" class=\"nounderline abstract_t\">Binder PS. Unusual manifestations of retinoblastoma. Am J Ophthalmol 1974; 77:674.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/9\" class=\"nounderline abstract_t\">Zakka KA, Yee RD, Foos RY. Retinoblastoma in a 12-year-old girl. Ann Ophthalmol 1983; 15:88.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/10\" class=\"nounderline abstract_t\">Shields JA, Michelson JB, Leonard BC, Thompson R. Retinoblastoma in an eighteen-year-old male. J Pediatr Ophthalmol 1976; 13:274.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/11\" class=\"nounderline abstract_t\">Shields CL, Shields JA, Shah P. Retinoblastoma in older children. Ophthalmology 1991; 98:395.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/12\" class=\"nounderline abstract_t\">Takahashi T, Tamura S, Inoue M, et al. Retinoblastoma in a 26-year-old adult. Ophthalmology 1983; 90:179.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/13\" class=\"nounderline abstract_t\">Biswas J. Unilateral retinoblastoma in an adult. Ophthalmology 1997; 104:1728.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/14\" class=\"nounderline abstract_t\">Berkeley JS, Kalita BC. Retinoblastoma in an adult. Lancet 1977; 2:508.</a></li><li class=\"breakAll\">Vogel F.. Genetics of retinoblastoma. In: Human Genetics: Problems and Approaches, Springer-Verlag, New York 1979. p.1.</li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/16\" class=\"nounderline abstract_t\">MacCarthy A, Birch JM, Draper GJ, et al. Retinoblastoma: treatment and survival in Great Britain 1963 to 2002. Br J Ophthalmol 2009; 93:38.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/17\" class=\"nounderline abstract_t\">Rubenfeld M, Abramson DH, Ellsworth RM, Kitchin FD. Unilateral vs. bilateral retinoblastoma. Correlations between age at diagnosis and stage of ocular disease. Ophthalmology 1986; 93:1016.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/18\" class=\"nounderline abstract_t\">Brichard B, Heusterspreute M, De Potter P, et al. Unilateral retinoblastoma, lack of familial history and older age does not exclude germline RB1 gene mutation. Eur J Cancer 2006; 42:65.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/19\" class=\"nounderline abstract_t\">Zhang J, Walsh MF, Wu G, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med 2015; 373:2336.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/20\" class=\"nounderline abstract_t\">Kleinerman RA, Schonfeld SJ, Tucker MA. Sarcomas in hereditary retinoblastoma. Clin Sarcoma Res 2012; 2:15.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/21\" class=\"nounderline abstract_t\">Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993; 85:1121.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/22\" class=\"nounderline abstract_t\">Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997; 278:1262.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/23\" class=\"nounderline abstract_t\">DerKinderen DJ, Koten JW, Nagelkerke NJ, et al. Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. Int J Cancer 1988; 41:499.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/24\" class=\"nounderline abstract_t\">Abramson DH, Melson MR, Dunkel IJ, Frank CM. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology 2001; 108:1868.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/25\" class=\"nounderline abstract_t\">Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 2007; 99:24.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/26\" class=\"nounderline abstract_t\">Finger PT, Harbour JW, Karcioglu ZA. Risk factors for metastasis in retinoblastoma. Surv Ophthalmol 2002; 47:1.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/27\" class=\"nounderline abstract_t\">Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323:643.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/28\" class=\"nounderline abstract_t\">Fung YK, Murphree AL, T'Ang A, et al. Structural evidence for the authenticity of the human retinoblastoma gene. Science 1987; 236:1657.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/29\" class=\"nounderline abstract_t\">Lee WH, Bookstein R, Hong F, et al. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987; 235:1394.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/30\" class=\"nounderline abstract_t\">Goodrich DW, Wang NP, Qian YW, et al. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 1991; 67:293.</a></li><li class=\"breakAll\">Hurwitz RL, Shields CL, Shields JA, et al.. Retinoblastoma. In: Principles and Practice of Pediatric Oncology, 6th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.809.</li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/32\" class=\"nounderline abstract_t\">Hansen MF, Koufos A, Gallie BL, et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A 1985; 82:6216.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/33\" class=\"nounderline abstract_t\">Knudson AG Jr, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci U S A 1975; 72:5116.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/34\" class=\"nounderline abstract_t\">Hethcote HW, Knudson AG Jr. Model for the incidence of embryonal cancers: application to retinoblastoma. Proc Natl Acad Sci U S A 1978; 75:2453.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/35\" class=\"nounderline abstract_t\">Xu XL, Singh HP, Wang L, et al. Rb suppresses human cone-precursor-derived retinoblastoma tumours. Nature 2014; 514:385.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/36\" class=\"nounderline abstract_t\">Francke U, Kung F. Sporadic bilateral retinoblastoma and 13q- chromosomal deletion. Med Pediatr Oncol 1976; 2:379.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/37\" class=\"nounderline abstract_t\">Motegi T. Lymphocyte chromosome survey in 42 patients with retinoblastoma: effort to detect 13q14 deletion mosaicism. Hum Genet 1981; 58:168.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/38\" class=\"nounderline abstract_t\">Kivel&auml; T, Tuppurainen K, Riikonen P, Vapalahti M. Retinoblastoma associated with chromosomal 13q14 deletion mosaicism. Ophthalmology 2003; 110:1983.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/39\" class=\"nounderline abstract_t\">Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444:61.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/40\" class=\"nounderline abstract_t\">Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012; 481:329.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/41\" class=\"nounderline abstract_t\">Otterson GA, Chen Wd, Coxon AB, et al. Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function. Proc Natl Acad Sci U S A 1997; 94:12036.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/42\" class=\"nounderline abstract_t\">Cast&eacute;ra L, Sabbagh A, Dehainault C, et al. MDM2 as a modifier gene in retinoblastoma. J Natl Cancer Inst 2010; 102:1805.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/43\" class=\"nounderline abstract_t\">Rushlow D, Piovesan B, Zhang K, et al. Detection of mosaic RB1 mutations in families with retinoblastoma. Hum Mutat 2009; 30:842.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/44\" class=\"nounderline abstract_t\">Smith BJ, O'Brien JM. The genetics of retinoblastoma and current diagnostic testing. J Pediatr Ophthalmol Strabismus 1996; 33:120.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/45\" class=\"nounderline abstract_t\">Rushlow DE, Mol BM, Kennett JY, et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol 2013; 14:327.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/46\" class=\"nounderline abstract_t\">McEvoy J, Nagahawatte P, Finkelstein D, et al. RB1 gene inactivation by chromothripsis in human retinoblastoma. Oncotarget 2014; 5:438.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/47\" class=\"nounderline abstract_t\">Lin P, O'Brien JM. Frontiers in the management of retinoblastoma. Am J Ophthalmol 2009; 148:192.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/48\" class=\"nounderline abstract_t\">Sanborn GE, Augsburger JJ, Shields JA. Spontaneous regression of bilateral retinoblastoma. Br J Ophthalmol 1982; 66:685.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/49\" class=\"nounderline abstract_t\">Kao LY, Yang ML. Spontaneous regression of retinoblastoma in a Taiwan series. J Pediatr Ophthalmol Strabismus 2005; 42:228.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/50\" class=\"nounderline abstract_t\">Khodadoust AA, Roozitalab HM, Smith RE, Green WR. Spontaneous regression of retinoblastoma. Surv Ophthalmol 1977; 21:467.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/51\" class=\"nounderline abstract_t\">Singh AD, Santos CM, Shields CL, et al. Observations on 17 patients with retinocytoma. Arch Ophthalmol 2000; 118:199.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/52\" class=\"nounderline abstract_t\">Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer 1996; 77:1206.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/53\" class=\"nounderline abstract_t\">Kim JW, Kathpalia V, Dunkel IJ, et al. Orbital recurrence of retinoblastoma following enucleation. Br J Ophthalmol 2009; 93:463.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/54\" class=\"nounderline abstract_t\">Leal-Leal CA, Rivera-Luna R, Flores-Rojo M, et al. Survival in extra-orbital metastatic retinoblastoma:treatment results. Clin Transl Oncol 2006; 8:39.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/55\" class=\"nounderline abstract_t\">Abramson DH. Second nonocular cancers in retinoblastoma: a unified hypothesis. The Franceschetti Lecture. Ophthalmic Genet 1999; 20:193.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/56\" class=\"nounderline abstract_t\">Butros LJ, Abramson DH, Dunkel IJ. Delayed diagnosis of retinoblastoma: analysis of degree, cause, and potential consequences. Pediatrics 2002; 109:E45.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/57\" class=\"nounderline abstract_t\">Margo CE, Zimmerman LE. Retinoblastoma: the accuracy of clinical diagnosis in children treated by enucleation. J Pediatr Ophthalmol Strabismus 1983; 20:227.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/58\" class=\"nounderline abstract_t\">Shields CL, Shields JA, Shields MB, Augsburger JJ. Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors. Ophthalmology 1987; 94:839.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/59\" class=\"nounderline abstract_t\">Shields JA, Shields CL, Parsons HM. Differential diagnosis of retinoblastoma. Retina 1991; 11:232.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/60\" class=\"nounderline abstract_t\">Yoshizumi MO, Thomas JV, Smith TR. Glaucoma-inducing mechanisms in eyes with retinoblastoma. Arch Ophthalmol 1978; 96:105.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/61\" class=\"nounderline abstract_t\">Abramson DH. Retinoblastoma 1990: diagnosis, treatment, and implications. Pediatr Ann 1990; 19:387.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/62\" class=\"nounderline abstract_t\">Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006; 113:2276.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/63\" class=\"nounderline abstract_t\">MacKay CJ, Abramson DH, Ellsworth RM. Metastatic patterns of retinoblastoma. Arch Ophthalmol 1984; 102:391.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/64\" class=\"nounderline abstract_t\">Shields CL, Ghassemi F, Tuncer S, et al. Clinical spectrum of diffuse infiltrating retinoblastoma in 34 consecutive eyes. Ophthalmology 2008; 115:2253.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/65\" class=\"nounderline abstract_t\">Berry JL, Jubran R, Wong K, et al. Factors predictive of long-term visual outcomes of Group D eyes treated with chemoreduction and low-dose IMRT salvage: the Children's Hospital Los Angeles experience. Br J Ophthalmol 2014; 98:1061.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/66\" class=\"nounderline abstract_t\">de Jong MC, Kors WA, de Graaf P, et al. Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol 2014; 15:1157.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/67\" class=\"nounderline abstract_t\">Kivel&auml; T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 1999; 17:1829.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/68\" class=\"nounderline abstract_t\">Ibarra MS, O'Brien JM. Is screening for primitive neuroectodermal tumors in patients with unilateral retinoblastoma necessary? J AAPOS 2000; 4:54.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/69\" class=\"nounderline abstract_t\">de Jong MC, Kors WA, de Graaf P, et al. The Incidence of Trilateral Retinoblastoma: A&nbsp;Systematic Review and Meta-Analysis. Am J Ophthalmol 2015; 160:1116.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/70\" class=\"nounderline abstract_t\">Chintagumpala M, Chevez-Barrios P, Paysse EA, et al. Retinoblastoma: review of current management. Oncologist 2007; 12:1237.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/71\" class=\"nounderline abstract_t\">Richter S, Vandezande K, Chen N, et al. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Hum Genet 2003; 72:253.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/72\" class=\"nounderline abstract_t\">Skalet AH, Gombos DS, Gallie BL, et al. Screening Children at Risk for Retinoblastoma: Consensus Report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology 2018; 125:453.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/73\" class=\"nounderline abstract_t\">Malkani I, Warrier RP, Yu LC, Ode DL. Retinoblastoma: a review. Indian J Pediatr 1993; 60:227.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/74\" class=\"nounderline abstract_t\">Char DH, Hedges TR 3rd, Norman D. Retinoblastoma. CT diagnosis. Ophthalmology 1984; 91:1347.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/75\" class=\"nounderline abstract_t\">Kaste SC, Jenkins JJ 3rd, Pratt CB, et al. Retinoblastoma: sonographic findings with pathologic correlation in pediatric patients. AJR Am J Roentgenol 2000; 175:495.</a></li><li class=\"breakAll\">Retinoblastoma - Europe. ONE Network, Available at: http://one.aao.org/topic-detail/retinoblastoma--europe (Accessed on November 25, 2014).</li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/77\" class=\"nounderline abstract_t\">Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001; 176:289.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/78\" class=\"nounderline abstract_t\">Benz MG, Benz MW. Reduction of cancer risk associated with pediatric computed tomography by the development of new technologies. Pediatrics 2004; 114:205.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/79\" class=\"nounderline abstract_t\">Frush DP, Donnelly LF, Rosen NS. Computed tomography and radiation risks: what pediatric health care providers should know. Pediatrics 2003; 112:951.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/80\" class=\"nounderline abstract_t\">de Graaf P, G&ouml;ricke S, Rodjan F, et al. Guidelines for imaging retinoblastoma: imaging principles and MRI standardization. Pediatr Radiol 2012; 42:2.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/81\" class=\"nounderline abstract_t\">Pratt CB, Meyer D, Chenaille P, Crom DB. The use of bone marrow aspirations and lumbar punctures at the time of diagnosis of retinoblastoma. J Clin Oncol 1989; 7:140.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/82\" class=\"nounderline abstract_t\">Mohney BG, Robertson DM. Ancillary testing for metastasis in patients with newly diagnosed retinoblastoma. Am J Ophthalmol 1994; 118:707.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/83\" class=\"nounderline abstract_t\">Smith EV, Gragoudas ES, Kolodny NH, D'Amico DJ. Magnetic resonance imaging: an emerging technique for the diagnosis of ocular disorders. Int Ophthalmol 1990; 14:119.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/84\" class=\"nounderline abstract_t\">Azar D, Donaldson C, Dalla-Pozza L. Questioning the need for routine bone marrow aspiration and lumbar puncture in patients with retinoblastoma. Clin Exp Ophthalmol 2003; 31:57.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/85\" class=\"nounderline abstract_t\">Palazzi M, Abramson DH, Ellsworth RM. Endophytic vs exophytic unilateral retinoblastoma: is there any real difference? J Pediatr Ophthalmol Strabismus 1990; 27:255.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/86\" class=\"nounderline abstract_t\">Shields CL, Shields JA, Baez K, et al. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer 1994; 73:692.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/87\" class=\"nounderline abstract_t\">Shields CL, Shields JA, Baez KA, et al. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol 1993; 77:544.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/88\" class=\"nounderline abstract_t\">Noorani HZ, Khan HN, Gallie BL, Detsky AS. Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma. Am J Hum Genet 1996; 59:301.</a></li><li class=\"breakAll\">Retinoblastoma Treatment in PDQ Cancer Information Summaries, available at: http://www.ncbi.nlm.nih.gov/books/NBK66006 (Accessed on March 31, 2016).</li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/90\" class=\"nounderline abstract_t\">Dhar SU, Chintagumpala M, Noll C, et al. Outcomes of integrating genetics in management of patients with retinoblastoma. Arch Ophthalmol 2011; 129:1428.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/91\" class=\"nounderline abstract_t\">Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 2005; 18:41.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/92\" class=\"nounderline abstract_t\">Pratt CB, Fontanesi J, Lu X, et al. Proposal for a New Staging Scheme for Intraocular and Extraocular Retinoblastoma Based on an Analysis of 103 Globes. Oncologist 1997; 2:1.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/93\" class=\"nounderline abstract_t\">Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol 2006; 17:228.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/94\" class=\"nounderline abstract_t\">Shields CL, Schoenberg E, Kocher K, et al. Lesions simulating retinoblastoma (pseudoretinoblastoma) in 604 cases: results based on age at presentation. Ophthalmology 2013; 120:311.</a></li><li><a href=\"https://www.uptodate.com/contents/retinoblastoma-clinical-presentation-evaluation-and-diagnosis/abstract/95\" class=\"nounderline abstract_t\">Maki JL, Marr BP, Abramson DH. Diagnosis of retinoblastoma: how good are referring physicians? Ophthalmic Genet 2009; 30:199.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6275 Version 35.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H31\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H3887962286\" id=\"outline-link-H3887962286\">TERMINOLOGY</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a><ul><li><a href=\"#H28685345\" id=\"outline-link-H28685345\">Incidence</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">Genetic predisposition</a></li></ul></li><li><a href=\"#H4\" id=\"outline-link-H4\">PATHOGENESIS</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">NATURAL HISTORY</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">CLINICAL PRESENTATION</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Clinical features</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Morphologic features</a></li><li><a href=\"#H2732413387\" id=\"outline-link-H2732413387\">Trilateral retinoblastoma</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Family history</a></li></ul></li><li><a href=\"#H2690789901\" id=\"outline-link-H2690789901\">SCREENING CHILDREN AT RISK</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">EVALUATION</a><ul><li><a href=\"#H1910567001\" id=\"outline-link-H1910567001\">Disease extent</a></li><li><a href=\"#H2022885934\" id=\"outline-link-H2022885934\">Metastatic evaluation</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Genetic testing</a></li></ul></li><li><a href=\"#H2153944203\" id=\"outline-link-H2153944203\">DIAGNOSIS</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">CLASSIFICATION</a></li><li><a href=\"#H4020183147\" id=\"outline-link-H4020183147\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H31\" id=\"outline-link-H31\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H1150401417\" id=\"outline-link-H1150401417\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/6275|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/98797\" class=\"graphic graphic_diagnosticimage\">- Pinealoblastoma MRI</a></li><li><a href=\"image.htm?imageKey=PEDS/98799\" class=\"graphic graphic_diagnosticimage\">- Retinoblastoma ultrasonography</a></li><li><a href=\"image.htm?imageKey=PEDS/72561\" class=\"graphic graphic_diagnosticimage\">- Calcified intraorbital mass</a></li><li><a href=\"image.htm?imageKey=PEDS/107994\" class=\"graphic graphic_diagnosticimage\">- Retinoblastoma on magnetic resonance imaging</a></li></ul></li><li><div id=\"PEDS/6275|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/73602\" class=\"graphic graphic_figure\">- Retinoblastoma formation</a></li><li><a href=\"image.htm?imageKey=PEDS/50453\" class=\"graphic graphic_figure\">- Retinoblastoma less than three years</a></li><li><a href=\"image.htm?imageKey=PEDS/68322\" class=\"graphic graphic_figure\">- Genetic counseling retinoblastoma</a></li></ul></li><li><div id=\"PEDS/6275|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/56724\" class=\"graphic graphic_picture\">- Unilateral leukocoria</a></li><li><a href=\"image.htm?imageKey=PEDS/74034\" class=\"graphic graphic_picture\">- Retinoblastoma strabismus</a></li><li><a href=\"image.htm?imageKey=PEDS/55803\" class=\"graphic graphic_picture\">- Combined exophytic-endophytic retinoblastoma</a></li><li><a href=\"image.htm?imageKey=PEDS/99046\" class=\"graphic graphic_picture\">- Retinoblastoma pathology</a></li></ul></li><li><div id=\"PEDS/6275|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/78948\" class=\"graphic graphic_table\">- Classification of retinoblastoma</a></li><li><a href=\"image.htm?imageKey=PEDS/88522\" class=\"graphic graphic_table\">- Genetic testing in retinoblastoma</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-child-with-leukocoria\" class=\"medical medical_review\">Approach to the child with leukocoria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-management-of-strabismus-in-children\" class=\"medical medical_review\">Evaluation and management of strabismus in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=microdeletion-syndromes-chromosomes-12-to-22\" class=\"medical medical_review\">Microdeletion syndromes (chromosomes 12 to 22)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenetic-factors-in-soft-tissue-and-bone-sarcomas\" class=\"medical medical_review\">Pathogenetic factors in soft tissue and bone sarcomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=retinoblastoma-treatment-and-outcome\" class=\"medical medical_review\">Retinoblastoma: Treatment and outcome</a></li></ul></div></div>","javascript":null}